Federico Cappuzzo

List of Publications by Year
in descending order

293 papers	37,014 citations	10351 72 h-index	3173 186 g-index
306 all docs	306 docs citations	306 times ranked	30255 citing authors

#	Article	IF	Citations
1	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 316, 1039-1043.	6.0	4,187
2	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
3	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 2018, 378, 2288-2301.	13.9	2,808
4	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	5.1	1,915
5	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Nonâ€“Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 643-655.	3.0	1,517
6	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269
7	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	9.4	1,186
8	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2010, 11, 521-529.	5.1	1,158
9	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	5.1	1,133
10	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, The, 2014, 384, 665-673.	6.3	1,068
11	Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, 62ra93.	5.8	761
12	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 387-401.	5.2	704
13	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	5.8	543
14	Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Nonâ€“Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2009, 27, 1667-1674.	0.8	530
15	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer, 2015, 112, 95-102.	2.9	515
16	Identifying and Targeting ROS1 Gene Fusions in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4570-4579.	3.2	405
17	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized PhaseÂIII Trial. Journal of Thoracic Oncology, 2020, 15, 1351-1360.	0.5	379
18	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1133-1141.	3.0	367

#	Article	IF	Citations
19	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptorâ€“Positive Nonâ€“Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	0.8	367
20	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 2015, 33, 992-999.	0.8	326
21	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Annals of Oncology, 2004, 15, 1042-1047.	0.6	322
22	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258.	0.8	308
23	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. Journal of Thoracic Oncology, 2017, 12, 15-26.	0.5	299
24	Role of gemcitabine in cancer therapy. Future Oncology, 2005, 1, 7-17.	1.1	288
25	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 2009, 20, 298-304.	0.6	286
26	Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 4113-4120.	0.8	280
27	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	0.5	273
28	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. Journal of Clinical Oncology, 2005, 23, 3279-3287.	0.8	264
29	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2007, 18, 752-760.	0.6	257
30	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of Oncology, 2016, 27, 281-286.	0.6	254
31	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 2009, 28, S32-S37.	2.6	246
32	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 2008, 19, 717-723.	0.6	243
33	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	5.8	239
34	Gefitinib Versus Vinorelbine in Chemotherapy-NaÃ¯ve Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. Journal of Clinical Oncology, 2008, 26, 4253-4260.	0.8	220
35	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridizationâ€“Positive/Phospho-Aktâ€“Positive or Never Smoker Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	0.8	218
36	HER2Mutation and Response to Trastuzumab Therapy in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2006, 354, 2619-2621.	13.9	217

#	Article	IF	Citations
37	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Nonâ€“Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology, 2016, 34, 2858-2865.	0.8	216
38	Gefitinib in Pretreated Nonâ€“Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. Journal of Clinical Oncology, 2003, 21, 2658-2663.	0.8	213
39	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 1909-1924.	0.5	212
40	Lung cancer screening with spiral CT. Lung Cancer, 2008, 59, 355-363.	0.9	179
41	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer, 2008, 99, 83-89.	2.9	167
42	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.. Journal of Clinical Oncology, 2018, 36, LBA9000-LBA9000.	0.8	153
43	Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer. Journal of Clinical Oncology, 2011, 29, 4789-4795.	0.8	150
44	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology, 2009, 20, 1674-1681.	0.6	147
45	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	3.2	139
46	HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. British Journal of Cancer, 2013, 108, 668-675.	2.9	131
47	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of Oncology, 2016, 27, 1291-1298.	0.6	129
48	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.. Journal of Clinical Oncology, 1996, 14, 2546-2551.	0.8	126
49	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 2019, 129, 35-40.	0.9	122
50	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer, 2003, 41, 227-231.	0.9	116
51	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews, 2012, 38, 416-430.	3.4	114
52	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology, 2022, 17, 309-323.	0.5	114
53	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer, 2011, 71, 249-257.	0.9	113
54	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	0.5	113

#	Article	IF	Citations
55	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
56	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. British Journal of Cancer, 2012, 107, 793-799.	2.9	109
57	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology, 2021, 16, 1547-1558.	0.5	108
58	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. British Journal of Cancer, 2008, 99, 51-56.	2.9	107
59	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	0.5	106
60	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. Journal of Clinical Pathology, 2009, 62, 970-977.	1.0	105
61	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
62	Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3078-3084.	3.2	97
63	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	0.6	93
64	ALKRearrangement in a Large Series of Consecutive Nonâ€“Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	1.2	93
65	Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. Neoplasia, 2009, 11, 1084-1092.	2.3	92
66	Gemcitabine and vinorelbine in pemetrexedâ€pretreated patients with malignant pleural mesothelioma. Cancer, 2008, 112, 1555-1561.	2.0	89
67	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Annals of Oncology, 2012, 23, 388-394.	0.6	87
68	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Nonâ€“Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology, 2016, 11, 545-555.	0.5	87
69	Genetic Abnormalities of the EGFR Pathway in African American Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5620-5626.	0.8	85
70	EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 423-429.	0.5	84
71	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study. Lung Cancer, 2013, 82, 231-237.	0.9	83
72	Use of nivolumab in elderly patients with advanced squamous nonâ€“small-cell lung cancer: results from the Italian cohort of an expanded access programme. European Journal of Cancer, 2018, 100, 126-134.	1.3	83

#	Article	IF	Citations
73	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget, 2017, 8, 13611-13619.	0.8	81
74	Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) Â± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.. Journal of Clinical Oncology, 2018, 36, 9002-9002.	0.8	78
75	microRNA classifiers are powerful diagnostic/prognostic tools in ALK- , EGFR- , and KRAS -driven lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14924-14929.	3.3	74
76	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer, 2005, 93, 1334-1340.	2.9	73
77	Primary pulmonary meningioma. Lung Cancer, 2008, 62, 401-407.	0.9	73
78	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	0.5	71
79	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology, 2010, 21, 562-567.	0.6	70
80	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. BJU International, 2019, 123, 98-105.	1.3	70
81	Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study. Nutrition, 1997, 13, 748-751.	1.1	68
82	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62.	2.9	68
83	Randomized phase <scp>II</scp> study of danusertib in patients with metastatic castrationâ€resistant prostate cancer after docetaxel failure. BJU International, 2013, 111, 44-52.	1.3	67
84	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. British Journal of Cancer, 2004, 90, 31-35.	2.9	66
85	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. Oncologist, 2010, 15, 1102-1112.	1.9	64
86	HER2 and lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 1219-1228.	1.1	63
87	Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs, 2012, 72, 28-36.	4.9	61
88	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	2.0	60
89	ROS1-rearranged Nonâ€“small-cell Lung Cancer isÂAssociated With a High Rate of VenousÂThromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms TrialÂ(METROS). Clinical Lung Cancer, 2020, 21, 15-20.	1.1	58
90	Blockage of interleukin-1Î² with canakinumab in patients with Covid-19. Scientific Reports, 2020, 10, 21775.	1.6	58

#	Article	IF	Citations
91	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular Diagnosis and Therapy, 2022, 26, 7-18.	1.6	57
92	Assessment of tumor response in malignant pleural mesothelioma. Cancer Treatment Reviews, 2007, 33, 533-541.	3.4	56
93	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
94	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Translational Lung Cancer Research, 2019, 8, 429-449.	1.3	54
95	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. International Journal of Oncology, 2013, 43, 765-774.	1.4	53
96	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer, 2004, 90, 82-86.	2.9	52
97	cMET Exon 14 Skipping: From the Structure to the Clinic. Journal of Thoracic Oncology, 2016, 11, 1423-1432.	0.5	51
98	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	2.0	50
99	MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib. Journal of Thoracic Oncology, 2009, 4, 472-478.	0.5	50
100	Clinical implications ofMETgene copy number in lung cancer. Future Oncology, 2010, 6, 239-247.	1.1	50
101	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂâ‰¥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	1.1	50
102	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer, 2014, 13, 37-45.e4.	1.0	46
103	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Translational Lung Cancer Research, 2017, 6, 373-386.	1.3	45
104	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2021, 22, 1438-1447.	5.1	45
105	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
106	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. British Journal of Cancer, 2003, 89, 246-247.	2.9	44
107	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.4	44
108	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220.	1.9	44

#	Article	IF	Citations
109	EGFR FISH versus mutation: Different tests, different end-points. Lung Cancer, 2008, 60, 160-165.	0.9	44
110	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2011, 6, 395-396.	0.5	44
111	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of Oncology, 2012, 23, 670-677.	0.6	44
112	First-line crizotinib versus pemetrexedâ€“cisplatin or pemetrexedâ€“carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Journal of Clinical Oncology, 2014, 32, 8002-8002.	0.8	44
113	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.. Journal of Clinical Oncology, 1995, 13, 2613-2619.	0.8	43
114	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer, 2011, 72, 3-8.	0.9	43
115	Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma. Cancer, 2003, 98, 128-134.	2.0	42
116	Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy, 2013, 13, 1401-1412.	1.4	42
117	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer, 2016, 93, 95-103.	0.9	41
118	The neuropilin 2 isoform NRP2b uniquely supports TGFÎ²-mediated progression in lung cancer. Science Signaling, 2017, 10, .	1.6	41
119	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 6006-6012.	3.2	40
120	Anaplastic lymphoma kinase gene rearrangements in cytological samples of nonâ€“small cell lung cancer: Comparison with histological assessment. Cancer Cytopathology, 2014, 122, 445-453.	1.4	40
121	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer, 2015, 87, 89-95.	0.9	40
122	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer, 2017, 112, 181-187.	0.9	40
123	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	1.1	40
124	HER2 in solid tumors: more than 10 years under the microscope; where are we now?. Future Oncology, 2014, 10, 1469-1486.	1.1	39
125	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. Journal of Clinical Pathology, 2012, 65, 218-223.	1.0	35
126	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921.	0.6	35

#	Article	IF	Citations
127	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. Oncologist, 2019, 24, e1165-e1171.	1.9	35
128	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7.	1.0	34
129	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy, 2013, 7, 61.	3.0	34
130	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology, 2006, 1, S13-9.	0.5	34
131	A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer, 2006, 52, 319-325.	0.9	33
132	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2006, 95, 45-53.	1.1	33
133	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers, 2015, 7, 556-573.	1.7	33
134	Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Current Opinion in Oncology, 2013, 25, 130-136.	1.1	32
135	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4.	1.1	32
136	Onartuzumab in lung cancer: the fall of Icarus?. Expert Review of Anticancer Therapy, 2015, 15, 487-489.	1.1	32
137	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	0.9	31
138	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	0.9	29
139	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer, 2005, 93, 29-34.	2.9	28
140	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	0.6	28
141	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 665-672.	0.5	28
142	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. Journal of Thoracic Oncology, 2021, 16, 2065-2077.	0.5	28
143	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Annals of Oncology, 2014, 25, 2156-2162.	0.6	26
144	Experience with erlotinib in the treatment of non-small cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 146-163.	1.0	25

#	Article	IF	Citations
145	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	1.4	25
146	Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib. The Application of Clinical Genetics, 2017, Volume 10, 49-56.	1.4	25
147	Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer, 2012, 76, 269-279.	0.9	24
148	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.3	24
149	Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?. Journal of the National Cancer Institute, 2005, 97, 868-869.	3.0	23
150	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
151	Rare mutations in non-small-cell lung cancer. Future Oncology, 2013, 9, 699-711.	1.1	23
152	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Translational Respiratory Medicine, 2014, 2, 2.	3.8	23
153	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	6.1	22
154	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). Oncotarget, 2018, 9, 17554-17563.	0.8	21
155	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational Lung Cancer Research, 2015, 4, 465-74.	1.3	21
156	Emerging drugs for small-cell lung cancer. Expert Opinion on Emerging Drugs, 2009, 14, 591-606.	1.0	20
157	Emerging drugs for small cell lung cancer â€“ an update. Expert Opinion on Emerging Drugs, 2012, 17, 31-36.	1.0	20
158	Irreversible EGFR-TKIs: dreaming perfection. Translational Lung Cancer Research, 2013, 2, 40-9.	1.3	20
159	Present and future treatment of advanced nonâ€“small cell lung cancer. Seminars in Oncology, 2002, 29, 9-16.	0.8	19
160	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 520-527.	0.5	19
161	Exposureâ€“response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 77-86.	1.1	18
162	Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology, 2010, 5, 5-17.	1.7	17

#	Article	IF	Citations
163	Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 523-533.	1.1	17
164	Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1203-1213.	0.9	17
165	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. Anticancer Research, 2020, 40, 983-990.	0.5	17
166	Phase II study of gemcitabineâ€“cisplatinâ€“paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. Lung Cancer, 2003, 42, 355-361.	0.9	16
167	Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2293-2305.	0.9	16
168	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		16
169	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 1525.	1.0	16
170	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. OncoTargets and Therapy, 2009, 2, 209.	1.0	15
171	Front-line therapy in lung cancer with mutations in EGFR. Nature Reviews Clinical Oncology, 2011, 8, 571-573.	12.5	15
172	Management of NSCLC: focus on crizotinib. Expert Opinion on Pharmacotherapy, 2014, 15, 2587-2597.	0.9	15
173	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	1.2	15
174	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. Oncotarget, 2019, 10, 561-572.	0.8	15
175	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. Future Oncology, 2018, 14, 1477-1486.	1.1	14
176	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.3	14
177	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers, 2020, 12, 2948.	1.7	14
178	1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. Annals of Oncology, 2020, 31, S817-S818.	0.6	14
179	1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Annals of Oncology, 2020, 31, S837-S838.	0.6	14
180	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncology, 2020, 16, 1433-1439.	1.1	14

#	Article	IF	Citations
181	Emerging drugs for non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2003, 8, 179-192.	1.0	13
182	Gefitinib for non-small-cell lung cancer treatment. Expert Opinion on Drug Safety, 2011, 10, 987-996.	1.0	13
183	Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer, 2014, 15, 470-474.	1.1	13
184	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. Drugs, 2016, 76, 831-840.	4.9	13
185	A noninterventional, multinational study to assess PDâ€L1 expression in cytological and histological lung cancer specimens. Cancer Cytopathology, 2020, 128, 928-938.	1.4	13
186	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiotherapy and Oncology, 2020, 149, 84-88.	0.3	13
187	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. Annals of Oncology, 2007, 18, ix150-ix155.	0.6	12
188	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	1.3	12
189	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103176.	2.0	11
190	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?. Current Drug Targets, 2014, 15, 1284-1292.	1.0	10
191	Gemcitabine in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 745-753.	0.9	9
192	MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer: Targets and Therapy, 2013, 4, 15.	1.3	9
193	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. PLoS ONE, 2015, 10, e0125037.	1.1	9
194	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. Drugs and Aging, 2015, 32, 907-916.	1.3	9
195	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	0.6	9
196	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2020, 14, 565-576.	1.0	9
197	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1783-1793.	1.2	8
198	1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. Annals of Oncology, 2020, 31, S814-S815.	0.6	8

#	Article	IF	Citations
199	Targeting MET in NSCLC: looking for a needle in a haystack. Translational Lung Cancer Research, 2014, 3, 389-91.	1.3	8
200	Management of Italian Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. Clinical Lung Cancer, 2014, 15, 338-345.e1.	1.1	7
201	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. Translational Lung Cancer Research, 2016, 5, 579-587.	1.3	7
202	Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial. Annals of Oncology, 2019, 30, v609-v610.	0.6	7
203	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431.	1.7	7
204	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	0.8	7
205	Activity of Formestane in de novo Tamoxifenâ€“Resistant Patients with Metastatic Breast Cancer. Oncology, 1995, 52, 454-457.	0.9	6
206	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14.	0.5	6
207	Is FISH floating or still swimming in the lung cancer ocean?. Annals of Oncology, 2011, 22, 493-499.	0.6	6
208	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. Journal of Thoracic Disease, 2016, 8, E1348-E1350.	0.6	6
209	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2016, 9, 203-214.	1.3	6
210	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. Tumor Biology, 2018, 40, 101042831881504.	0.8	6
211	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	2.0	6
212	How selecting best upfront therapy for metastatic disease?â€”Focus on ROS1-rearranged disease. Translational Lung Cancer Research, 2020, 9, 2686-2695.	1.3	6
213	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	6
214	A Real-World Systematic Analysis of Driver Mutationsâ€™ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting. Cancers, 2022, 14, 2971.	1.7	6
215	C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). Journal of Thoracic Oncology, 2007, 2, S359-S360.	0.5	5
216	PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology, 2016, 11, S302-S303.	0.5	5

#	Article	IF	Citations
217	HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?. Clinical Cancer Research, 2018, 24, 2470-2472.	3.2	5
218	COVIDâ€19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. Breast Journal, 2021, 27, 359-362.	0.4	5
219	New targeted therapies for non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 335-350.	0.2	4
220	Consequences of targeted treatments for second-line therapy. Annals of Oncology, 2010, 21, vii234-vii240.	0.6	4
221	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-NaÃ¯ve Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology, 2017, 12, S1296-S1297.	0.5	4
222	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. Clinical and Translational Oncology, 2020, 22, 294-301.	1.2	4
223	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 669839.	1.3	4
224	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. Journal of Clinical Oncology, 2014, 32, 11035-11035.	0.8	4
225	Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8101-8101.	0.8	4
226	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9079-9079.	0.8	4
227	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 461-462.	3.0	3
228	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186.	1.7	3
229	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nsclc in Profile 1014. Annals of Oncology, 2014, 25, v2.	0.6	3
230	Minimizing Aircraft ECS Bleed Off-Take - Virtual Integrated Aircraft Applications. SAE International Journal of Aerospace, 2016, 9, 151-162.	4.0	3
231	Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063. Cancer Research, 2017, 77, CT126-CT126.	0.4	3
232	Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.. Journal of Clinical Oncology, 2012, 30, 474-474.	0.8	3
233	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
234	First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly â€˜unfrailâ€™ patients with advanced non-small-cell lung cancer: a multicenter phase II study. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2003-2008.	1.2	2

#	Article	IF	Citations
235	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data inÂSquamous Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, S1336-S1337.	0.5	2
236	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. Journal of Thoracic Disease, 2018, 10, 3883-3890.	0.6	2
237	ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. Annals of Oncology, 2019, 30, v658.	0.6	2
238	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). Annals of Oncology, 2020, 31, S1078.	0.6	2
239	Crizotinib in ROS1 and MET Deregulated NSCLCâ€"Response. Clinical Cancer Research, 2020, 26, 1775-1775.	3.2	2
240	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. Journal of Thoracic Disease, 2012, 4, 226-8.	0.6	2
241	Ceritinib for the treatment of non-small cell lung cancer. Drugs of Today, 2014, 50, 465.	0.7	2
242	RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 462-463.	3.0	1
243	Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791.	1.5	1
244	Is gemcitabine cost effective in cancer treatment?. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 239-249.	0.7	1
245	M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification. Journal of Thoracic Oncology, 2007, 2, S156-S157.	0.5	1
246	D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology, 2007, 2, S396.	0.5	1
247	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2014, 5, 43.	1.3	1
248	PUB076 Programmed Cell Death Ligand 1 and Neutrophil to Lymphocyte Ratio to Predict Response to Nivolumab in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S2390-S2391.	0.5	1
249	P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial. Journal of Thoracic Oncology, 2019, 14, S553.	0.5	1
250	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. Oral Oncology, 2021, 115, 105133.	0.8	1
251	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. Journal of Clinical Oncology, 2017, 35, e20656-e20656.	0.8	1
252	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2019, 37, TPS9121-TPS9121.	0.8	1

#	Article	IF	Citations
253	Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.. Journal of Clinical Oncology, 2016, 34, TPS9103-TPS9103.	0.8	1
254	Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. Journal of Clinical Oncology, 2017, 35, e20676-e20676.	0.8	1
255	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: â€œSurvival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiouslyâ€. Journal of Thoracic Oncology, 2022, 17, e40-e41.	0.5	1
256	Induction treatments in marginally operable non-small cell lung cancer. European Journal of Cancer, 1999, 35, S386.	1.3	0
257	Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. Lung Cancer, 2001, 34, 45-47.	0.9	0
258	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1795-1795.	3.0	0
259	Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275.	0.2	0
260	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in nonâ€“small cell lung cancer: a promising feature?. Human Pathology, 2010, 41, 614-615.	1.1	0
261	The Role of ERBB Family Blockade in NSCLC. The Journal of Oncopathology, 2014, 2, 51-58.	0.1	0
262	The role of research nurse in translational studies: LUCAS experience. Annals of Oncology, 2015, 26, vi113.	0.6	0
263	Nit-Picking around second line inEGFR NSCLC: just an academic effort. Annals of Oncology, 2015, 26, 448-450.	0.6	0
264	P2.06-016 Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy. Journal of Thoracic Oncology, 2017, 12, S1079-S1080.	0.5	0
265	MTE26.02 EGFR Targeted Therapies: Lessons Learned. Journal of Thoracic Oncology, 2017, 12, S177-S178.	0.5	0
266	A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay. Journal of Thoracic Disease, 2017, 9, 2311-2314.	0.6	0
267	PC07.04 Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO. Journal of Thoracic Oncology, 2018, 13, S247-S248.	0.5	0
268	Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. Annals of Oncology, 2018, 29, viii644.	0.6	0
269	P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial. Journal of Thoracic Oncology, 2018, 13, S464-S465.	0.5	0
270	Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial. Annals of Oncology, 2019, 30, v659-v660.	0.6	0

#	Article	IF	Citations
271	Chemoimmunotherapy for stage IV non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2019, 20, e467.	5.1	0
272	P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S563-S564.	0.5	0
273	Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?. Journal of Thoracic Oncology, 2020, 15, e92-e93.	0.5	0
274	Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events. , 2010, , .		0
275	Abstract 3195: HMGA1 and HMGA2 over-expression in human lung carcinoma. , 2011, , .		0
276	MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, e21018-e21018.	0.8	0
277	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. Journal of Clinical Oncology, 2013, 31, 11058-11058.	0.8	0
278	Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations.. Journal of Clinical Oncology, 2013, 31, 11066-11066.	0.8	0
279	The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function. , 2014, , 7-17.		0
280	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.		0
281	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. Journal of Clinical Oncology, 2014, 32, 11056-11056.	0.8	0
282	Resistance to anti-angiogenic drugs and therapeutic options. , 2015, , 61-66.		0
283	Overcoming EGFR-TKI Resistance. , 2015, , 37-50.		0
284	Resistance to EGFR TKIs. , 2015, , 27-36.		0
285	Therapy options for advanced NSCLC. , 2015, , 5-25.		0
286	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. Journal of Clinical Oncology, 2015, 33, 11076-11076.	0.8	0
287	Abstract 4853: NRP2b, a unique isoform of NRP2, promotes aggressive lung cancer phenotypes. , 2017, , .		0
288	Lung Cancer Update 2017: from the test tube to the bed. Annals of Translational Medicine, 2018, 6, 86-86.	0.7	0

#	Article	IF	Citations
289	Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment. Translational Cancer Research, 2018, 7, S549-S552.	0.4	0
290	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. Journal of Clinical Oncology, 2019, 37, e20688-e20688.	0.8	0
291	Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC. , 2019, , .		0
292	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. Annals of Translational Medicine, 2015, 3, 32.	0.7	0
293	EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation. Translational Lung Cancer Research, 2012, 1, 160-2.	1.3	0